Butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of CYP3A4 inducers may perhaps decrease sufentanil ranges and efficacy, perhaps precipitating withdrawal syndrome in sufferers who have formulated Bodily dependence to sufentanil. Discontinuation of concomitantly utilised CYP3A4 in... https://stepheny875prn2.illawiki.com/user